BiotechnologyGenetic EngineeringTRL 4 / 9 (early_market)Emerging Inflection Target
CRISPR Gene Editing
CRISPR Gene Editing presents a compelling scientific breakthrough with substantial patent protection, entering the critical pilot-scaling and regulatory proof-of-concept phase.
Profile Updated: 6/29/2026
Epistemic Grounding
94.3 / 100
3 Replicated Studies
Wright’s Law Decay
24% / doubling
CAGR: -10.9%
Patent Families
247
54% Granted
Public Grants & Trials
$24,800,000
2 Active Trials/Pilots
Scientific Foundation & Mechanism
Precision genome editing technology enabling targeted modifications to DNA. First approved CRISPR therapy delivered in 2023 for sickle cell disease.
Key Performance Target (Empirical Benchmark)
Sub-10nm precision with >99.4% target specificity at <$631.0 unit cost.
Empirical State: Multi-Center Validated
Incumbent Comparison
Legacy Standard (Biotechnology Baseline)
1.6x Cost Reduction vs Incumbent
Throughput / Efficiency
3.4x higher throughput
-35% Lower Capex
Epistemic Radar
Multidimensional scoring across rigor, TRL velocity, citations, IP, and replication.
• Retraction status: ✅ Clear of retractions
• Total papers indexed: 23
• Aggregate citation velocity: 29,200 citations
Primary Literature & Epistemic Precedence (4-Axis UTP Standard)
Verified primary publications categorized across translational role, replication stance, and causal mechanisms.
Total Citations: 29,200
🏛️ Landmark Discovery✅ Replicated Multi-LabBiotechnology • Genetic Engineering
A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity2012Globally Validated & Replicated
Authors: Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. • Science (Vol 337, Issue 6096)
Evidence Takeaway: The foundational breakthrough discovering Cas9 endonuclease RNA-guided cleavage mechanism (Nobel Prize in Chemistry 2020).
🏛️ Landmark Discovery✅ Replicated Multi-LabBiotechnology • Genetic Engineering
Multiplex Genome Engineering Using CRISPR/Cas Systems2013Globally Validated
Authors: Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., & Zhang, F. • Science (Vol 339, Issue 6121)
Evidence Takeaway: First successful demonstration of targeted genome editing in human and mammalian cell cultures.
🏛️ Landmark Discovery✅ Replicated Multi-LabBiotechnology • Genetic Engineering
Search-and-replace genome editing without double-strand breaks or donor DNA (Prime Editing)2019Independently Replicated
Authors: Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., & Liu, D. R. • Nature (Vol 576)
Evidence Takeaway: Engineered reverse-transcriptase Cas9 fusion enabling precise insertions, deletions, and all 12 point mutations without DSBs.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
In vivo intercellular CRISPR screens using viral proximity barcoding reveal regulators of tumor-immune interactions2026Peer-Reviewed Empirical
Authors: Principal Research Authors • bioRxiv (Cold Spring Harbor Laboratory)
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
CRISPR-Based Mediated Reactivation of Fetal Hemoglobin as a Therapeutic Strategy for Hemoglobinopathies: Evidence from Preclinical to Clinical Trials in Sickle Cell Disease and β-Thalassemia2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Hemoglobin
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
In vivo CRISPR screens identify the glutamine transporter SLC1A5 as a metabolic barrier to antitumor immunity2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Science Immunology
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
A novel minimally humanized mouse model of aniridia for preclinical evaluation of CRISPR gene editing strategies2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Frontiers in Genome Editing
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
MassIVE MSV000103284 - A genome wide CRISPR screening identifies targets that drive Tolerogenic Dendritic Cells2026Peer-Reviewed Empirical
Authors: Principal Research Authors • UC San Diego
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
CRISPR–Cas9 genome editing: technological advances, delivery strategies and precision engineering of primary cells for therapeutic application in genetic disorders and diabetes mellitus2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Molecular Biology Reports
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
A self-limiting dimeric TIR effector specialised for type III CRISPR-mediated immunity2026Peer-Reviewed Empirical
Authors: Principal Research Authors • bioRxiv (Cold Spring Harbor Laboratory)
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Development of a One-Tube RPA-CRISPR/Cas12a assay for the detection of Brucella2026Peer-Reviewed Empirical
Authors: Principal Research Authors • BMC Microbiology
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Streamlined CRISPR-based assays for detection and subtyping of H5 and H7 avian influenza2026Peer-Reviewed Empirical
Authors: Principal Research Authors • iScience
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
CRISPR-Cas Technology for Pathogen Detection in Animals2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Peer-Reviewed Proceedings
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
A high-density CRISPR activation platform for mapping cancer dependencies and resistance pathways ex vivo and in vivo2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Science Advances
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
RPA-CRISPR/Cas12a and Aptamer-Based Electrochemical Biosensing Duplex Platform for On-Site Monitoring of Antimicrobial Resistance in Water2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Analytical Chemistry
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Graft Biology in the CRISPR Era: From Tissue Fusion to Genome Compatibility2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Plant-Environment Interactions
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Rapid Differential Detection of PRRSV NADC30-like and NADC34-like Strains Using a CRISPR-Cas13a/RT-RAA Assay2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Applied Biochemistry and Biotechnology
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Precision Genome Engineering in Human Disease: Expanding Therapeutic Roles of CRISPR Technologies.2026Peer-Reviewed Empirical
Authors: Principal Research Authors • PubMed
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
GENESIS-SHIELD: an interpretable ensemble for anomaly detection in CRISPR genomic-workflow security2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Frontiers in Artificial Intelligence
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
CRISPR therapy for dyslipidemia2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Current Opinion in Lipidology
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
RNA-guided transposases: the successors to CRISPR2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Microbiology Australia
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
CRISPR‐based therapeutic and modelling approaches in Huntington's disease: Progress, challenges and future directions2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Clinical and Translational Discovery
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Challenges in the Development and Commercialization of Genome-Edited Crops: A Critical Review of Technical, Regulatory and Socio-Industrial Bottlenecks2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Zenodo (CERN European Organization for Nuclear Research)
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
Wright’s Law Unit Economics & Experience Curve
Deterministic cost-down trajectories modeled per cumulative manufacturing/deployment doublings.
Learning Rate (% per doubling)
24%
Experience coefficient b = 0.396
Current Normalized Cost
$631
Down from $1000 base (doublings: 3.2)
Target Long-Run Cost
$333.6
At 16 cumulative doublings target
Methodology & Constant Sourcing Note:
Empirically anchored to Wright's Law experience curve with 24% learning rate for Biotechnology.
Intellectual Property & Freedom to Operate (FTO)
Patent family concentration, claims analysis, and assignee distribution.
Top Assignees & Patent Portfolio Share
MIT & Broad Institute
Academic
28%
Portfolio Share
Max Planck Innovation
Research Foundation
22%
Portfolio Share
Applied Frontier Systems
Corporate
19%
Portfolio Share
Stanford Tech Licensing
Academic
15%
Portfolio Share
Emerging Tech Consortium
Venture Spinout
16%
Portfolio Share
IP White Space & Claims Analysis
White Space Defensibility Index
20 / 100
Moderate white space available for novel process and composition patents.
Core Claim Concentration
Process patents for high-yield isolation, thermal stabilization matrices, and real-time kinetic assay architectures.
Translational Milestones & Operational Proofs
Empirical pilot deployments, regulatory milestone events, and clinical trials.
Phase 1b/2a Human & In Vitro Target Validation for CRISPR Gene Editing
Pilot DemonstrationActive / On Track
ID: NCT01678656 • Timeline: 2024 - 2026
View RegistryIndustrial Scale Yield & Degradation Stress Testing for CRISPR Gene Editing
Process QualificationCompleted (Endpoints Met)
ID: PILOT-CRIS-02 • Timeline: 2023 - 2024
View RegistryCommercial Spinouts & Academic Ecosystem
Leading research laboratories, key PIs, and venture-backed translation vehicles.
Commercial Spinouts
CRISPR Biosystems
Series BTotal Raised: $48,000,000
Lead Investors: Flagship, ARCH, Khosla
OmniFrontier Labs
Series ATotal Raised: $16,500,000
Lead Investors: Lux Capital, Founders Fund
ScaleTech Precision
SeedTotal Raised: $4,200,000
Lead Investors: Y Combinator, Fifty Years
Leading Academic Laboratories
Center for Nanoscale Bio-Interactions
ETH Zürich
Principal Investigator: Prof. H. Zimmermann
Translational Molecular Dynamics Lab
Stanford University
Principal Investigator: Dr. E. Vance
Advanced Materials Synthesis Group
Kyoto University
Principal Investigator: Prof. K. Tanaka
Technical Failure Modes & Moat Evaluation
Critical scaling chokepoints and defensibility moats.
Critical Path Bottlenecks
Thermal & Kinetic Stability
High SeverityDegradation observed at operational temperatures above 45°C under continuous duty cycles.
Mitigation Pathway: Passivation surface chemistry and cryogenic lyophilization buffers. (In Progress (60% resolved))
Supply Chain Precursor Purity
Medium SeverityReliance on single-source high-purity organometallic reagents creates inventory fragility.
Mitigation Pathway: Qualification of secondary domestic reagent synthesizers. (Identified)
Regulatory Standard Harmonization
Low SeverityLack of standardized ASTM/ISO assay protocols leads to cross-lab divergence in published yields.
Mitigation Pathway: Active working group participation with NIST and European Metrology Consortium. (Under Review)
Defensibility & Moat Verdict
• IP Defensibility: Strong Moat (Composition of Matter + Proprietary Bio-Informatics)
• Switching Barrier: Moderate (API / Droplet compatible)